Annexon, Inc. (ANNX): Total Assets
$277.57M
As of 2025-12-31
$246.07M
As of 2026-06-30
-0.9%
3-year compound annual growth
-4.9%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $277.57M | -20.7% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $350.07M | +17.6% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $297.67M | +4.4% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $285.10M | -0.7% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $287.04M | -19.4% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $355.95M | +613.3% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $49.90M | n/a | 2021-03-25, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Annexon, Inc. (ANNX) | 2025-12-31 | $277.57M | -20.7% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $277.17M | +70.2% |
| Contineum Therapeutics, Inc. (CTNM) | 2025-12-31 | $276.64M | +30.0% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $279.93M | +100.9% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $280.41M | -7.7% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $280.73M | -25.5% |
| Tyra Biosciences, Inc. (TYRA) | 2025-12-31 | $282.61M | -22.3% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $271.15M | -21.2% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $284.73M | +59.8% |
Compare ANNX, TNXP, CTNM, ALT side by side · Screen every company in Pharmaceutical Preparations ↗